SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
PFE Analysis & Videos »
PFE: Bull or Bear?
A 130 / 30 Global Pharma ETF Strategy
PFE
|
|
|
-10.10%
in
31 days
<> Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent expiration exposure over the next 2-3 years includes Pfizer (NYSE: PFE ), GlaxoSmithKline (NYSE: GSK ), Takeda Pharma (OTC: TKPHY.PK ), Sanofi-Aventis ( SNY ), AstraZeneca ( AZN ), and Merck ( MRK ).
...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
PFE
|
|
|
+20.76%
in
217 days
(closed on 11/04/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Big Pharma Goes Generic
PFE
|
|
|
-6.13%
in
34 days
(closed on 04/01/09)
<> <> <> <> <> <>  Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
|
A 130/30 Pharma Trade
PFE
|
|
|
+4.48%
in
6 days
(closed on 02/26/09)
By Mike Havrilla on 2/20/09 ETF Innovators The tables at my website link below include 12 U.S. listed companies from the ETF Innovators Global Generic Drug Index along with seven brand drug companies, which are ranked in descending order based on their patent expiration exposure through the end of 2011 as a percentage of total trailing 12-month revenue. <> Investors who are bullish on the generic drug industry may consider implementing a 130/30 pharma trade by shorting any/all...
|
Trading the Trials and FDA Decision Calendar
PFE
|
|
|
-16.03%
in
27 days
(closed on 02/20/09)
Trading the Trials and FDA Decision Calendar The tables at my website links below feature an updated calendar of 80 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and click here for a list of 14 extreme trades of companies with market caps below $100M and pending new drug decisions at the FDA. <> Below is a summary of the major updates on the calendar...
|
Cramer on BloggingStocks: Cramer bullish on the Dow for '09 -- Part V
PFE
-6.79%
in
199 days
(closed on 07/27/09)
Filed under: General Electric (GE), Pfizer (PFE), Wal-Mart (WMT), Exxon Mobil (XOM), AT and T (T), Target Corp. (TGT), Johnson and Johnson (JNJ), Comcast Cl'A' (CMCSA), Procter and Gamble (PG), Lowe's Cos (LOW), Verizon Communications (VZ), Merck and Co (MRK), United Technologies (UTX), DJIA, Stocks to Buy, Cramer on BloggingStocks TheStreet.com's Jim Cramer sees a stalled industrial and a winning retail play in this final portion of his 2009 predictions.
This is the...
|
Pfizer 'admits' it's in trouble
PFE
-3.56%
in
333 days
Filed under: Bad news, Pfizer (PFE), Stocks to Sell  In a period of economic distress, owning stocks with stable cash flows is a great way to avoid the carnage found in other parts of the market. One sector traditionally known to provide consistent cash flow to investors is the pharmaceutical industry.
Patent protection on drugs provides the industry with the ability to generate revenue unencumbered by competition. Investors generally pay a premium to own a piece of that stream -- no matter what is happening in the economy. <>During the last few years, market premium for drug companies has been d...
|
Drug and health care stocks: The right prescription for 2009
PFE
-29.20%
in
64 days
(closed on 03/10/09)
Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Bristol-Myers Squibb (BMY), Stocks to Buy, Best Stocks for 2009  Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.
<>In this year's Top Stock Picks from 75 advisors report, we found an intriguing group of medical-related stocks, from speculation in emerging biotech to well-established pharmaceutical firms, and from medical pr...
|
Stock Ideas from ETF Innovators New Indexes
PFE
|
|
|
-2.37%
in
47 days
(closed on 01/24/09)
<> Below is a list of 14 stock opportunities from various ETF Innovators [ETFI] indexes, which includes a database of over 1,000 companies. The companies are chosen across a full spectrum of market cap and risk level from a variety of industry groups.
From the ETFI Highly Defensive PerformIdex , I believe Altria Group (MO) and Pfizer (PFE) are defensive dividend, value buys at current levels as each company currently pays a dividend of $1.28 per share annually – resulting in historically high dividend yields for bot<>< />< /><><><>< />< /><><><>< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><>< />< /><><><><>< />< />< />< />< />< />< />< />...
|
A More Focused Highly Defensive Index
PFE
|
|
|
+6.64%
in
4 days
(closed on 12/07/08)
<> 
The accompanying table [click to enlarge] includes an updated version of the ETF Innovators [ETFI] ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups.
(A) Mass Merch...
|
Stock Picks for Healthy Returns
PFE
|
|
|
-3.18%
in
8 days
(closed on 12/03/08)
<> Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X.
Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one.
...
|
A New Global Healthcare Composite Index
PFE
|
|
|
+2.38%
in
2 days
(closed on 11/25/08)
<> 
The accompanying table [click to enlarge or download] presents the top five rated companies with market caps of at least $250M from each of the 10 new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 500 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 50 top rated companies on an equal weight basis from each of the 10 new healthcare indexes as an alternative strategy to existing health composite ETFs with highly correlated returns and over-weight exposure to th...
|
People Bullish on PFE
People Bearish on PFE
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
|
|
|
|
tanumoy
(+117.03% risk: conservative)
|
|
|
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
More Resources
|
About Pfizer Inc
- Answers.com
"The silver lining to the market decline is that some of our favorite stocks have fallen into 'buy' territory," says 
"We're not bullish on stocks until we see an improving economy; but if I had to choose a top pick for 2009, I have no problems choosing 
